![[Lung Cancer Immunotherapy] FDA Approved Libtayo (Cemiplimab) as First-Line Choice for PD-L1 High-Expression Non-Smal...](/_next/image?url=%2Fimages%2Fblog%2Ffdaapproveslybtayofornon-smallcelllungcancer-0.webp&w=3840&q=75)
[Lung Cancer Immunotherapy] FDA Approved Libtayo (Cemiplimab) as First-Line Choice for PD-L1 High-Expression Non-Small Cell Lung Cancer
[Lung Cancer Immunotherapy] FDA Approves Libtayo as First-Line Treatment Choice
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
For advanced non-small cell lung cancer (NSCLC) patients, immunotherapy has risen from later-line treatment to become a first-line core option. The U.S. FDA and relevant Japanese regulatory authorities have approved Libtayo (Cemiplimab) for patients with high PD-L1 expression (TPS ≥ 50%) and without EGFR, ALK, or ROS1 gene mutations.
I. EMPOWER-Lung 1 Trial: A Substantial Leap in Survival
This randomized, open-label trial compared Libtayo monotherapy with conventional platinum-based chemotherapy, showing overwhelming advantages.
Core Clinical Data:
- Median Overall Survival (OS): The Libtayo group achieved 22.1 months, significantly better than the chemotherapy group's 14.3 months.
- Progression-Free Survival (PFS): Median of 6.2 months, demonstrating better disease control.
- Objective Response Rate (ORR): The Libtayo group achieved 37%, demonstrating strong tumor-shrinking ability.
II. Safety and Adverse Event Management
While Libtayo has good tolerability, immune-related adverse events (irAE) still require professional monitoring:
- Common Reactions: Musculoskeletal pain, rash, anemia, and fatigue.
- Important Indicators: Pneumonitis and cough require close attention, as these need precise differentiation from disease progression in lung cancer patients.
III. Why First-Line Treatment Choice Is Crucial
In cancer treatment, the first-line regimen often determines the subsequent treatment space. The addition of Libtayo allows patients with high PD-L1 expression to avoid some of the side effects of traditional chemotherapy while achieving longer survival. Leading Japanese hospitals (such as Cancer Institute Ariake, National Cancer Center) have world-leading experience in adverse event warning and management for such immune checkpoint inhibitors.
Medical Supporter: Your Guide to Precision Lung Cancer Treatment Facing complex immunotherapy choices, you need professional advice. Medical Supporter can arrange remote video consultations with Japan's top lung cancer specialists, help you evaluate PD-L1 expression levels, and formulate the most appropriate medical treatment plan in Japan.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4